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ABSTRACT
Background SARS- CoV-2 lineage B.1.1.7 has been 
associated with an increased rate of transmission and 
disease severity among subjects testing positive in the 
community. Its impact on hospitalised patients is less 
well documented.
Methods We collected viral sequences and clinical 
data of patients admitted with SARS- CoV-2 and 
hospital- onset COVID-19 infections (HOCIs), sampled 
16 November 2020 to 10 January 2021, from eight 
hospitals participating in the COG- UK- HOCI study. 
Associations between the variant and the outcomes 
of all- cause mortality and intensive therapy unit (ITU) 
admission were evaluated using mixed effects Cox 
models adjusted by age, sex, comorbidities, care home 
residence, pregnancy and ethnicity.
Findings Sequences were obtained from 2341 inpatients 
(HOCI cases=786) and analysis of clinical outcomes was 
carried out in 2147 inpatients with all data available. The HR 
for mortality of B.1.1.7 compared with other lineages was 1.01 
(95% CI 0.79 to 1.28, p=0.94) and for ITU admission was 1.01 
(95% CI 0.75 to 1.37, p=0.96). Analysis of sex- specific effects 
of B.1.1.7 identified increased risk of mortality (HR 1.30, 95% CI 
0.95 to 1.78, p=0.096) and ITU admission (HR 1.82, 95% CI 
1.15 to 2.90, p=0.011) in females infected with the variant but 
not males (mortality HR 0.82, 95% CI 0.61 to 1.10, p=0.177; 
ITU HR 0.74, 95% CI 0.52 to 1.04, p=0.086).
Interpretation In common with smaller studies of 
patients hospitalised with SARS- CoV-2, we did not 
find an overall increase in mortality or ITU admission 
associated with B.1.1.7 compared with other lineages. 
However, women with B.1.1.7 may be at an increased 
risk of admission to intensive care and at modestly 
increased risk of mortality.
INTRODUCTION
The emergence of SARS- CoV-2 lineage 
B.1.1.7 in South East England has been 
found to be associated with an estimated 70% 
increased rate of community transmission 
compared with previously circulating vari-
ants.1–3 Lineage B.1.1.7 became the dominant 
lineage in the UK in winter 2020/2021. It 
has also been detected in over 120 countries 
outside the UK,4 and was assigned the label of 
variant of concern Alpha by WHO.5
Lineage B.1.1.7 has acquired an unusually 
large number of mutations and deletions 
in a short period of time1–3; specifically 14 
Key messages
 ► In a multicentre cohort we did not find an overall 
increase in mortality or intensive therapy unit ad-
mission associated with B.1.1.7 among hospitalised 
patients, but women with B.1.1.7 may be at an in-
creased risk of admission to intensive care and at 
modestly increased risk of mortality.
 ► The impact of SARS- CoV-2 lineage B.1.1.7 on dis-
ease severity appears to be dependent on the pa-
tient’s sex, meaning that its health impacts and 
healthcare burden will differ from earlier lineages 
of the virus and that monitoring of disease course 
by sex should be considered for other viral lineages 
with increased transmissibility.
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non- synonymous single nucleotide polymorphisms and 
3 amino acid deletions, with 8 of these 17 amino acid 
changes occurring in the spike protein, responsible for 
receptor binding and a major immunogenic target. At 
least three of the spike protein changes are associated 
with in vitro biological changes. A tyrosine substitution 
at position 501 in the spike protein receptor binding 
domain has been shown to increase binding to the ACE2 
receptor, while deletion of spike protein amino acids 
69/70 reduces antibody neutralisation by convalescent 
sera.6 7 The potential that so many mutations might 
change B.1.1.7 virulence has been examined epidemi-
ologically using data largely from community- collected 
samples.8–11 However, there are few data on the impact 
of B.1.1.7 infection as compared with other variants on 
disease outcomes in hospitalised patients.
We investigated the potential associations between 
the B.1.1.7 variant and the outcomes of mortality and 
intensive therapy unit (ITU) admission both in patients 
admitted with COVID-19 and hospital onset COVID-19 
infections (HOCIs) in the COG- UK- HOCI study. The 
main objective was to estimate the overall effect of the 
variant on each of these outcomes, and we also evaluated 
whether the impact of the variant differed according to 
patient characteristics.
METHODS
Sequence and patient meta-data
Data were collected from five NHS hospitals within 
London and three outside. The first SARS- CoV-2- positive 
sample from all inpatients tested through hospital labo-
ratories between 16 November 2020 and 10 January 2021 
was sequenced. In addition, metadata were collected 
from clinical records on patient age, sex (as binary M/F), 
comorbidities as identified by the COVID-19 Green-
book12 (including obesity with body mass index ≥35 kg/
m2), care home residence, pregnancy, ethnicity, date of 
hospital admission, ward location and first SARS- CoV-2- 
positive test for all samples plus dates of admission to the 
ITU and all- cause death where these events occurred.
Inpatients were classified as those admitted with 
SARS- CoV-2 plus cases which were identified after admis-
sion, with the latter termed HOCI cases and subdivided 
into indeterminate healthcare- associated infections 
(HCAIs) diagnosed 3–7 days after admission and prob-
able/definite HCAIs diagnosed ≥8 days postadmission.13 
The primary outcomes for analysis were the events of 
death and of ITU admission. Events were included in the 
analysis within 28 days of hospital admission for those 
admitted with COVID-19 and within 28 days of diagnosis 
for HOCI cases.
SARS-CoV-2 sequencing
Samples were sequenced by Nanopore or Illumina 
methods as part of the COVID-19 Genomics UK Consor-
tium (COG- UK). To maximise success, 4/8 labs sequenced 
only those samples with quantitative PCR cycle thresholds 
(ct) values of ≤32 or equivalent. Sequences were assigned 
to lineages using COG- UK Pangolin.14
Statistical analysis
Only patients with admission to hospital and HOCIs 
were included in the statistical analysis of the clinical 
outcomes of mortality and ITU admission. Mortality and 
ITU admission were modelled as time- to- event outcomes, 
from time of hospital admission for those admitted with 
COVID-19 and from time of diagnosis for HOCI cases, 
censored at 28 days. Analyses of ITU admission were 
also censored at patient death. Both outcomes were 
censored at date of data collection for these variables for 
each site (between 15 January and 22 February 2021). 
Mixed effects Cox models were used with adjustment for 
sex, patient age (using 5- knot restricted cubic spline), 
number of comorbidities (none, one, two, ≥three), care 
home residence, pregnancy, ethnicity (white, black, 
Asian, mixed or other) and sample week with separate 
parameters for London sites and for other sites grouped 
using the R package coxme V.2.2–16.15 A 5- knot restricted 
cubic spline16 was used for patient age in all analyses to 
allow flexibility in modelling the relationship with each 
outcome while maintaining a consistent model structure. 
Random intercept terms were included to reflect clus-
tering of outcomes within hospital and weekly periods 
nested within hospitals. Cox models were stratified by 
HOCI status (allowing for different baseline hazard 
functions in patients admitted with COVID-19 vs HOCI 
groups).
Outcomes were analysed on a complete case basis with 
regard to patient characteristics. This decision was based 
on the availability of complete data for >90% of patients 
and the fact that Cox regression gives asymptotically unbi-
ased estimates of an association of interest as long as the 
missingness is not dependent on both outcome (ie, death 
or ITU admission) and exposure (B.1.1.7 status).17 18 The 
variable of obesity was analysed as ‘morbid obesity’ versus 
‘no record of morbid obesity’ on examination of case 
notes, and was included in statistical models within the 
ordinal comorbidities variable.
The primary aim of the analysis was to estimate the 
overall association between the B.1.1.7 vs non- B.1.1.7 
strain and the risk of each of the outcomes considered. 
Exploratory secondary analyses also evaluated inter-
actions between B.1.1.7 status and patient characteris-
tics in estimating the effect on each outcome. Analyses 
were conducted in R V.4.0.2, using tidyverse collection 
of packages with all plots generated using ggplot2 and 
survminer.19–22
Patient and public involvement
This was an analysis of retrospectively collected data, for 
which the planning, data collection and analysis were all 
carried out during a period of extreme pressure on the 
UK health service due to the COVID-19 epidemic. As 
such, there was no patient and public engagement in the 
Stirrup O, et al. BMJ Open Resp Res 2021;8:e001029. doi:10.1136/bmjresp-2021-001029 3
Open access
conduct of this research and it would not be possible to 
disseminate the findings directly to participants.
RESULTS
Study dataset
Between 16 November 2020 and 10 January 2021, 
SARS- CoV-2 RNA- positive upper respiratory tract samples 
from 2341 inpatients were sequenced from the eight 
participating sites (table 1 and online supplemental 
figure S1). Analysis of clinical outcomes was carried out 
in 2147 inpatients with all data available. The prevalence 
of lineage B.1.1.7 was highest in London and Hampshire 
(South of England), but substantially increased at all sites 
over the study period (online supplemental figure S2).
Mortality outcome
Death within 28 days was reported in 527 (22.5%) of the 
2341 patients. Death was recorded as having occurred 
following discharge with date of death missing in five, 
and these patients have been excluded from anal-
yses. Death within 28 days was recorded in 494/2147 
(23.0%) of the patients with all data available, with full 
28 days of follow- up in 939/1653 (56.8%) of the other 
patients. On mixed effects multivariable Cox regression, 
the overall HR for mortality of lineage B.1.1.7 was 1.01 
(95% CI 0.79 to 1.28, p=0.94) (figure 1, online supple-
mental table S1). Male sex was found to be a substan-
tial risk factor for mortality (HR 1.46 vs female, 95% CI 
1.22 to 1.75; p<0.001) and age was also strongly associ-
ated with the risk of death (figure 2). The risk of death 
was higher in care home residents (HR 1.39, 95% CI 1.02 
to 1.90, p=0.04) and those with one or more significant 
comorbidities (HR 1.78 (95% CI 1.26 to 2.52) for one 
comorbidity, 2.03 (95% CI 1.43 to 2.88) for two and 2.89 
(95% CI 2.04 to 4.08) for ≥three versus none; p<0.001). 
Those with ethnicity other than white were estimated to 
be at higher risk of death, but ethnicity was not a statisti-
cally significant predictor when evaluated over all catego-
ries (p=0.36). No pregnant women died and so this vari-
able was dropped from the model as a perfect predictor.
The addition of an interaction term between B.1.1.7 
status and patient sex for the effect on mortality led to an 
improvement in model fit (p=0.01 interaction test, p=0.04 
lineage B.1.1.7 effects by sex vs no B.1.1.7 effect, on likeli-
hood ratio tests (LRT)). The estimated HR for mortality 
of lineage B.1.1.7 vs non- B.1.1.7 was 0.82 (95% CI 0.61 
to 1.10, p=0.177) in male patients and 1.30 (95% CI 0.95 
to 1.78, p=0.096) in female patients. No improvement to 
model fit was provided by the addition of an interaction 
between B.1.1.7 status and patient age (p=0.48, LRT with 
4 df), ethnicity (p=0.67, LRT with 3 df) or comorbidity 
category (p=0.33, LRT with 3 df).
A statistically significant interaction was found between 
the effect of B.1.1.7 and care home residence (p=0.03, 
LRT with 1 df), with those care home residents with 
B.1.1.7 infection estimated to be at lower risk of death (HR 
0.52, 95% CI 0.27 to 1.02, p=0.057) with a non- significant 
Table 1 Proportion of SARS- CoV-2 due to lineage B.1.1.7 












  0–11 15 (62.5) 9 (37.5) 24 (100)
  12–24 20 (58.8) 14 (41.2) 34 (100)
  25–34 61 (62.9) 36 (37.1) 97 (100)
  35–49 159 (56.2) 124 (43.8) 283 (100)
  50–69 371 (53.2) 326 (46.8) 697 (100)
  70–79 208 (42.2) 285 (57.8) 493 (100)
  80+ 273 (38.3) 440 (61.7) 713 (100)
Sex
  Female 534 (46.1) 624 (53.9) 1158 (100)
  Male 573 (48.4) 610 (51.6) 1183 (100)
Sample week starting
  16 November 2020 15 (8.4) 164 (91.6) 179 (100)
  23 November 2020 26 (11.6) 198 (88.4) 224 (100)
  30 November 2020 59 (24.2) 185 (75.8) 244 (100)
  07 December 2020 55 (26.8) 150 (73.2) 205 (100)
  14 December 2020 138 (43.8) 177 (56.2) 315 (100)
  21 December 2020 220 (54.6) 183 (45.4) 403 (100)
  28 December 2020 361 (75.2) 119 (24.8) 480 (100)
  04 January 2021 233 (80.1) 58 (19.9) 291 (100)
Patient class
  HCW 7 (36.8) 12 (63.2) 19 (100)
  CAI* 847 (55.1) 689 (44.9) 1536 (100)
  Indeterminate HCAI† 54 (25.4) 159 (74.6) 213 (100)
  Probable/definite 
HCAI‡
199 (34.7) 374 (65.3) 573 (100)
Region
  Glasgow 91 (31.6) 197 (68.4) 288 (100)
  Hampshire 74 (60.2) 49 (39.8) 123 (100)
  London 871 (65.7) 455 (34.3) 1326 (100)
  South Yorkshire 71 (11.8) 533 (88.2) 604 (100)
Ethnicity
  White 540 (39.4) 829 (60.6) 1369 (100)
  Black 174 (53.4) 152 (46.6) 326 (100)
  Asian 118 (63.1) 69 (36.9) 187 (100)
  Mixed or other 186 (67.1) 91 (32.9) 277 (100)
  Unknown 89 (48.9) 93 (51.1) 182 (100)
Patient characteristics
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increase in the risk for death associated with B.1.1.7 for 
non- care home residents (1.09, 95% CI 0.85 to 1.41, 
p=0.49). We attempted to fit a model including inter-
action on both sex and care home residence status, but 
convergence of parameter estimates failed. The model 
with interaction on sex had the lowest Akaike informa-
tion criterion of all fitted models and, given also the rela-
tively small number of care home residents in the dataset, 
we therefore focus on this model for interpretation and 
analysis.
Kaplan- Meier plots of mortality in relation to B.1.1.7 
status are presented according to patient sex and age 
categories in figure 3 (also provided separately for non- 
HOCI and HOCI inpatients in online supplemental 
figures S3 and S4, with HR estimates in online supple-
mental table S2).
ITU admission outcome
Admission to ITU within 28 days was reported in 337 
(14.4%) of 2341 inpatients (excluding 46 HOCI cases 
diagnosed after admission to ITU). On mixed effects 
multivariable Cox regression, the overall HR for ITU 
admission for lineage B.1.1.7 was 1.01 (95% CI 0.75 
to 1.37, p=0.94) (figure 1, online supplemental table 
S1). Within this model, male sex was a substantial risk 
factor for ITU admission (HR 1.33, 95% CI 1.05 to 1.68; 
p=0.02). Age was also strongly associated with the risk 
of ITU admission, although the relationship estimated 
was non- linear with the greatest risk of this outcome at 
65 years of age (figure 2). The risk of ITU admission 
was higher in those with one or two significant comor-
bidities (HR 1.25 (95% CI 0.92 to 1.71) for one comor-
bidity, 1.24 (95% CI 0.89 to 1.74) for two and 0.79 (95% 
CI 0.54 to 1.15) for ≥three versus none; p=0.03). Those 
with ethnicity other than white were estimated to be at 
higher risk of ITU admission, but ethnicity was not a 
statistically significant predictor evaluated over all cate-
gories (p=0.09). Pregnant women were found to be at 
lower risk of ITU admission (HR 0.13, 95% CI 0.02 to 
0.98, p=0.048).
The addition of an interaction term between B.1.1.7 
status and patient sex for the effect on ITU admission 
led to an improvement in model fit (p=0.0004 inter-
action test, p=0.002 lineage B.1.1.7 effects by sex vs no 
B.1.1.7 effect, LRTs). The estimated HR for ITU admis-
sion for lineage B.1.1.7 vs non- B.1.1.7 was 0.74 (95% CI 
0.52 to 1.04, p=0.086) in male patients and 1.82 (95% 
CI 1.15 to 2.90, p=0.011) in female patients. There was 
no evidence for an interaction of B.1.1.7 status with 
patient age (p=0.11, LRT with 4 df), ethnicity (p=0.74, 
LRT with 3 df), comorbidity category (p=0.79, LRT with 
3 df), pregnancy (p=0.42, LRT with 1 df) or care home 
residence (p=0.24, LRT with 1 df) with ITU admission 
as the outcome. Kaplan- Meier plots of ITU admission 
in relation to B.1.1.7 status are presented according to 
patient sex and age categories in figure 4 (also provided 
separately for non- HOCI and HOCI inpatients in online 
supplemental figures S5 and S6, with HR estimates in 
online supplemental table S2).
DISCUSSION
Our findings provide the largest dataset on disease severity 
in hospitalised patients with lineage B.1.1.7 and the only 
one based on routine sequencing of all specimens from 
multiple hospitals. The overall hazard of mortality and 
ITU were unchanged for patients with lineage B.1.1.7 in 
comparison to other viral variants (HR 1.01, 95% CI 0.79 
to 1.28 and HR 1.01, 95% CI 0.75 to 1.37, respectively). 
These findings are in line with the results of a much 
smaller analysis of 341 (n=198 with B.1.1.7) hospital inpa-
tients with viral sequencing over a similar time period in 
London, which found an adjusted mortality risk ratio 
for B.1.1.7 of 1.02 (95% CI 0.76 to 1.38).23 However, in 
contrast with this smaller study we also found evidence 
that B.1.1.7 infection appears to have a different impact 
on the disease course according to sex among hospital-
ised patients with SARS- CoV-2 infection, with increased 
hazard of both mortality and ITU admission associated 
with the variant for female but not male patients.
Several larger studies of disease severity in the UK 
have used PCR Spike (S) gene target failure (SGTF) as a 
surrogate for lineage B.1.1.7.8–11 These studies, based on 
community testing data, all found evidence of an overall 
increased risk of mortality associated with lineage B.1.1.7, 

















  None 337 (56.6) 258 (43.4) 595 (100)
  One 307 (47.3) 342 (52.7) 649 (100)
  Two 261 (45.9) 308 (54.1) 569 (100)
  Three or more 202 (38.4) 324 (61.6) 526 (100)
  Not recorded 0 (0) 2 (100) 2 (100)














Data shown as n (%), with (N) with available data shown where 
missing values possible.
*Diagnosed at or ≤2 days from admission.
†Diagnosed 3–7 days from admission. 
‡Diagnosed ≥8 days from admission.
§Excluding patients admitted to ITU prior to SARS- CoV-2 
diagnosis.
BMI, body mass index; CAI, community- acquired infection; HCAI, 
healthcare- associated infection; HCW, healthcare worker; ITU, 
intensive therapy unit.
Table 1 Continued
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Figure 1 Results of mixed effect Cox regression models for death and intensive therapy unit (ITU) admission, shown as HR 
(●, ■ for reference categories) with 95% CI. Results are displayed for outcomes of mortality (A, B) and ITU admission (C, D), 
both for the overall effect of B.1.1.7 variant (A, C) and with sex- specific effects of B.1.1.7 (B, D). Models were all also adjusted 
by age using natural cubic splines (as shown in figure 2).
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Challen et al,8 1.55 (95% CI 1.39 to 1.72) by Davies et al,9 
1.67 (95% CI 1.34 to 2.09) by Grint et al10 and 1.59 (95% 
CI 1.25 to 2.03) by Patone et al.11 In the UK, SGTF is only 
available as a marker for a subset of those patients who 
were first positive for SARS- CoV-2 on testing within the 
community; most people who die of COVID-19 were not 
previously tested within the community8 and the relevant 
PCR assay is not used by all laboratories, meaning that 
SGTF status is only available for 8.6% of deaths.9 SGTF 
is an imperfect predictor of lineage B.1.1.7, and is much 
less accurate as a marker when prevalence of the variant 
is low (before mid- November 2020 in the UK).24
The apparent overall differences in mortality risk 
observed in the SGTF analyses in comparison to our 
study do not necessarily represent inconsistent findings. 
Studies that are limited to patients who test positive in 
the community may be subject to selection biases linked 
to propensity to present for testing or rapidity of disease 
progression, while analyses that include only data from 
inpatients will not reflect the characteristics of the popu-
lation as a whole. For example, increased disease severity 
may result in a higher proportion of subjects reaching 
the threshold for admission to hospital but not affect the 
mortality rate among those who are admitted to hospital. 
Our study also includes a subset of patients with probable 
nosocomial infection, whose characteristics and comor-
bidity profile differs greatly from the UK population as 
whole.25
Individuals testing positive in the community for an 
SGTF- associated variant had higher risk of hospitalisa-
tion, with OR of 1.58 (95% CI 1.50 to 1.67).26 This result 
was confirmed by a study of national health register- 
data from Denmark including 18 499 patients with viral 
genomes available in the period 1 January to 9 February 
2021 which found an adjusted OR of 1.64 (95% CI 1.32 to 
2.04) for hospitalisation for B.1.1.7 compared with other 
lineages.27 Taken together with the findings regarding 
mortality in the UK,8–11 these results are consistent with 
an increased risk of mortality and hospitalisation among 
patients testing positive for B.1.1.7 in the community 
but no overall increase in mortality among the subset of 
patients admitted to hospital.
We found a significantly increased risk of both 
mortality (30%) and ITU admission (82%) in hospi-
talised female patients infected with B.1.1.7 but not in 
male patients. In contrast, studies of community- tested 
individuals found no interaction with sex for the effect 
of B.1.1.7 on mortality,9 11 critical care admission11 or 
risk of hospitalisation.26 However, these studies were all 
conducted among patients who first tested positive for 
SARS- CoV-2 within the community, and therefore they 
cannot rule out an interaction with sex for the impact 
of B.1.1.7 on disease severity among all people infected 
with the virus or among all those admitted to hospital. 
Nationally collated data show that females accounted 
for 33.2% of patients admitted to ITU with COVID-19 
in London, East and South East England between 1 
September and 30 November 2020 rising to 36.2%, 
between 1 December 2020 and 21 January 2021 when 
lineage B.1.1.7 predominated.28
There is evidence that the total number of pregnant 
women requiring intensive care in the UK was higher in 
late 2020/early 2021 in comparison to the first wave of 
the COVID-19 epidemic in Spring 2020,29 and that the 
proportion of symptomatic pregnant women requiring 
admission to ITU increased as lineage B.1.1.7 became 
dominant.30 This would be consistent with a differential 
impact of the B.1.1.7 variant on women in comparison 
to men. However, we should also note that our analyses 
found pregnancy itself to be negatively associated with 
Figure 2 Plots of estimated HR for (A) death and (B) intensive therapy unit (ITU) admission in relation to age for mixed 
effects Cox regression models with single overall effect of B.1.1.7 variant (95% CIs shown as dotted lines). Following from the 
parameterisation of the model, HRs are shown relative to hazard at age of 31 years.
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ITU admission, conditional on age, sex, viral variant, 
comorbidities and other patient characteristics. This 
could possibly be due to unobserved or residual 
confounding not fully captured by our recording and 
analysis of patient characteristics.
An impact of lineage B.1.1.7 on females that is not 
observed in males could potentially be explained by physi-
ological differences. For example, increased ACE2 expres-
sion in females has been posited as one explanation for 
the relatively lower mortality and morbidity observed for 
COVID-19 for women in comparison to men.31 32 Lineage 
B.1.1.7 has mutations that increase binding of the viral 
spike protein to ACE2, thereby providing a plausible 
mechanism by which the new variant might have a differ-
ential effect on disease severity in males and females.6 31 33 
Our results suggest a reduction in the risk of mortality 
or ITU admission associated with B.1.1.7 in comparison 
to other viral lineages among male inpatients, although 
this finding was not definitive with HR 95% CIs that 
included no effect for both outcomes. However, this is 
against a backdrop of the established increased risk for 
male versus female patients for pre- B.1.1.7 strains.34 Our 
results indicate an approximate equalisation of risk for 
otherwise equivalent male and female inpatients with 
B.1.1.7 infection.
Although ours is substantially the largest study of 
hospitalised patients with confirmed lineage B.1.1.7 
and non- B.1.1.7 SARS- Cov-2 infection, it has a number 
of limitations. Primarily, while evaluation of disease 
severity among only hospital inpatients can give useful 
Figure 3 Kaplan- Meier plots of all- cause mortality among all inpatients in relation to lineage B.1.1.7 status, plotted 
according to patient sex and age categories. Date of sampling is used as the ‘zero’ time point for hospital- onset COVID-19 
infections, with date of admission used for other patients. Naïve 95% CIs are plotted for illustrative purposes (these are not 
derived from the multilevel Cox models described).
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information on disease course and progression, analysis 
of only these patients cannot provide information on 
disease severity across all SARS- CoV-2 infections in the 
population as a whole. In addition, ITU admission can 
be difficult to interpret as a measure of disease severity 
among inpatients. For instance, admission to ITU may 
reflect the presence of severe disease and local deci-
sions around the benefit or lack thereof to frail patients, 
which may be influenced by bed numbers and availability 
of respiratory support in non- critical care settings. Our 
primary analysis also includes cases of hospital- acquired 
infection but exclusion of these HOCI cases from our 
analyses yielded similar findings (online supplemental 
table S2).
A further limitation of our analysis is that we do not have 
any information on vaccination status for individual patients. 
Our dataset covers a period in which a national vaccination 
programme was being initiated for HCWs and the elderly 
population in the UK, starting with those aged 80 years and 
above from 8 December 2020. This is a potential explanation 
for the observed protective interaction effect between care 
home residence and B.1.1.7 on mortality, as care home resi-
dents were prioritised for vaccination around the time that 
this viral variant was increasing in prevalence. Vaccine break-
through infections are well described, particularly in partially 
vaccinated subjects.35
Our analysis was focused on the effect of lineage B.1.1.7 
as a single exposure of interest for each outcome variable. 
Figure 4 Kaplan- Meier plots of intensive therapy unit (ITU) admission among all inpatients in relation to lineage B.1.1.7 
status, plotted according to patient sex and age categories. Date of sampling is used as the ‘zero’ time point for hospital- 
onset COVID-19 infections, with date of admission used for other patients. Naïve 95% CIs are plotted for illustrative purposes 
(these are not derived from the multilevel Cox models described).
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However, we also considered 5 potential interactions with 
viral lineage for the outcome of mortality and 6 for ITU 
admission, giving a total of 13 hypothesis tests of interest. 
A conservative use of the Bonferroni correction gives a p 
value cut- off adjusted to 0.0038 from the commonly used 
threshold of 0.05, using which we would consider there to 
be robust statistical evidence for an interaction with sex 
on the outcome of ITU admission but not for the interac-
tions between sex or care home status on mortality.
Implications
Although lineage B.1.1.7 was not associated with an 
overall increase in mortality among hospitalised patients, 
our investigation suggests that lineage B.1.1.7 may be asso-
ciated with higher ITU admission and death in females 
compared with non- B.1.1.7 within this group. The domi-
nance of lineage B.1.1.7 in the UK precluded further 
comparison with earlier non- B.1.1.7 variants, and there 
is now concern regarding the spread of other lineages 
in the UK and elsewhere.36 There is a need for ongoing 
large- scale sequencing of SARS- CoV-2 cases linked to 
data on patient characteristics and outcomes in order to 
generate timely information regarding the associations 
between viral lineages and disease severity. Monitoring of 
disease course by sex should be considered for other viral 
lineages with increased transmissibility.
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